Evaluation of Purple Town
NCT07919639, Not applicable, Completed, Paris Nanterre University
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Evaluation of Purple Town | ClinicalTrials.gov |
| NCT number | NCT07919639 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 352 participants, actual | ClinicalTrials.gov |
| Lead sponsor | Paris Nanterre University | ClinicalTrials.gov |
| Conditions | Alcohol Use, Cannabis Use, Health Literacy | ClinicalTrials.gov |
| Interventions | Purple Town prevention program, Purple town mobile game | ClinicalTrials.gov |
| First posted | 2026-11-05 | ClinicalTrials.gov |
| Last updated | 2026-11-05 | ClinicalTrials.gov |
Registered outcomes 8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Skepticism Toward Marketing Scale score | Baseline (T1) and 2-week follow-up (T2) | Assessed using the Skepticism Toward Marketing Scale. Measured on a 5-point Likert scale ranging from 1 ("Strongly disagree") to 5 ("Strongly agree"). Total scores range from a minimum of 10 to a maximum of 50 for alcohol marketing, and from 10 to 35 for cannabis marketing. Higher scores indicate greater critical skepticism toward marketing (a better outcome). | ClinicalTrials.gov |
| Primary | Substance Knowledge Questionnaire score | Baseline (T1) and 2-week follow-up immediately post-intervention (T2) | Assessed using the Knowledge About Substance Use Questionnaire (True/False/Don't know items). Correct answers receive 1 point and incorrect/don't know answers receive 0 points. Total scores range from a minimum of 0 to a maximum of 10 for alcohol knowledge, and from 0 to 13 for cannabis knowledge. Higher scores indicate greater factual knowledge (a better outcome). | ClinicalTrials.gov |
| Primary | Awareness of Marketing Influence Strategies Questionnaire score | Baseline (T1) and 2-week follow-up immediately post-intervention (T2) | Assessed using the Awareness of Marketing Influence Strategies Questionnaire. Measured on a 5-point Likert scale ranging from 1 ("Never") to 5 ("Always"). Total scores range from a minimum of 9 to a maximum of 45 for alcohol, and from 5 to 25 for cannabis. Higher scores indicate greater awareness of marketing strategies (a better outcome). | ClinicalTrials.gov |
| Primary | Protective Behavioral Intentions Questionnaire score | Baseline (T1) and 2-week follow-up immediately post-intervention (T2) | Assessed using the Protective Behavioral Intentions Questionnaire. Measured on a 5-point Likert scale ranging from 1 ("Not at all likely") to 5 ("Very likely"). Total scores range from a minimum of 5 to a maximum of 25 for alcohol, and from 5 to 25 for cannabis. Higher scores indicate a stronger intention to adopt risk reduction strategies (a better outcome). | ClinicalTrials.gov |
| Primary | Alcohol and Cannabis Lifetime Use Questionnaire Status | Baseline (T1) and 2-week follow-up immediately post-intervention (T2) | Assessed using self-administered questions evaluating lifetime experimentation with alcohol and cannabis (binary outcome: Yes/No) | ClinicalTrials.gov |
| Secondary | In-game Application Telemetry Logs | Over the 15-day intervention period | Objective usage data recorded directly by the Purple Town mobile game server, collected as the total number of completed game sessions per participant. | ClinicalTrials.gov |
| Secondary | Attitudes Toward Substance Use Semantic Differential Scale score | Baseline (T1) and 2-week follow-up immediately post-intervention (T2) | Assessed using the Attitudes Toward Substance Use Osgood Semantic Differential Scale (9 bipolar adjective pairs). Each item is rated on a 7-point scale ranging from 1 to 7. Total scores range from a minimum of 7 to a maximum of 63. Higher scores indicate more positive attitudes toward substance use (a worse/more favorable toward risky behavior outcome). | ClinicalTrials.gov |
| Secondary | Substance Use Intentions Questionnaire score | Baseline (T1) and 2-week follow-up immediately post-intervention (T2) | Assessed using the Substance Use Intentions Questionnaire. Measured on a 5-point Likert scale ranging from 1 ("Not at all likely") to 5 ("Very likely"). Scores range from a minimum of 1 to a maximum of 5 per item. Higher scores indicate higher intention to consume substances (a worse outcome). | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)